Imunon, Inc.

Listed Company

IMNNCIK 0000749647NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-14.50M

Total Assets

$12.29M

Equity

$7.06M

Shares Out

3.92M

Op. Cash Flow

$-13.90M

Business

Imunon, Inc. is a clinical-stage biotechnology company developing non-viral DNA and mRNA delivery technologies to produce therapeutic proteins and vaccine antigens for difficult-to-treat diseases. It offers therapeutic immunotherapies and vaccine candidates, most notably IMNN-001 (a DNA-based IL-12 immunotherapy for ovarian cancer) and PLACCINE/IMNN-101 DNA vaccine candidates delivered via its TheraPlas synthetic delivery system. The company’s activities are organized around two principal modalities—TheraPlas for protein/cytokine expression and PLACCINE for multivalent DNA vaccines—and include clinical development, translational research, manufacturing and collaborative trials. Imunon conducts clinical trials and partnerships primarily in the United States and Europe, uses third-party CMOs for supply, and plans commercialization through direct efforts or strategic alliances.

Summary from filing dated 2025-02-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	8	12	11	12	11
General and administrative	7	7	10	14	11
Total operating expenses	15	19	21	25	22
Loss from operations	−15	−19	−21	−25	−21
Investment income, net	155,666	512,204	1	453,356	10,996
Total other income, net	155,666	512,204	235,068	−13	−1
Net loss	−15	−19	−20	−36	−21
Net loss per common share - basic	−6.83	−16.94	−2.16	−5.03	−3.83
Net loss per common share - diluted	−6.83	−16.94	−2.16	−5.03	—
Weighted average common shares outstanding - basic	2	1	9	7	5
Weighted average common shares outstanding - diluted	2	1	9	7	—

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	9	6	6	11	20
Advances and deposits on clinical programs and other current assets	2	2	3	2	2
Total current assets	11	8	18	37	52
Property and equipment (at cost, less accumulated depreciation and amortization)	529,936	541,272	751,906	548,301	477,011
Operating lease right-of-use assets, net	984,436	1	2	155,876	690,995
Deposits and other assets	50,000	50,000	50,000	425,000	183,489
Total other assets	1	1	3	7	22
Total assets	12	10	22	44	74
Accounts payable trade	1	1	4	—	—
Other accrued liabilities	3	3	3	5	3
Operating lease liabilities - current portion	406,354	452,358	485,421	230,749	548,870
Total current liabilities	5	5	7	10	7
Operating lease liabilities - non-current portion	602,411	686,935	1	—	230,749
Total liabilities	5	5	9	15	18
Commitments and contingencies	—	—	—	—	—
Preferred Stock - $0.01 par value (100,000 shares authorized, and no shares issued or outstanding at December 31, 2025 and 2024)	—	—	—	—	—
Common stock - $0.01 par value (350,000,000 and 112,500,000 shares authorized at December 31, 2025 and 2024, respectively; 3,419,652 and 966,714 shares issued at December 31, 2025 and 2024, respectively, and 3,419,650 and 966,712 shares outstanding at December 31, 2025 and 2024, respectively)	34,197	9,667	93,998	74,362	57,705
Additional paid-in capital	428	411	402	398	389
Accumulated deficit	−421	−407	−388	−369	−333
Total stockholders equity before treasury stock	7	4	13	29	56
Treasury stock, at cost (2 shares at December 31, 2025 and 2024)	−85,188	−85,188	−85,188	−85,188	−85,188
Total stockholders equity	7	4	13	29	56
Total liabilities and stockholders equity	12	10	22	44	74

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation	291,908	240,175	248,154	196,510	—
Amortization of right-of-use assets	406,992	477,941	471,851	535,119	—
Realized losses, net, on investment securities	—	−61,983	34,302	—	—
Stock-based compensation	127,374	477,256	759,013	3	4
Fair value of shares issued in exchange for services	99,040	—	—	—	—
Non-cash effect of reverse stock split	704	—	—	—	—
Realization of deferred income tax asset	—	1	286,641	−183,580	462,377
Advances, deposits, and other current assets	193,507	408,859	−141,619	—	−124,728
Accounts payable and accrued liabilities	−521,121	−3	−2	—	—
Net cash used in operating activities	−14	−19	−19	−23	−16
Purchases of investment securities	—	−57,174	−14	−48	−54
Proceeds from sale and maturity of investment securities	—	10	25	57	24
Purchases of property and equipment	−280,572	−29,541	−451,759	−267,800	−311,613
Net cash (used in) provided by investing activities	−280,572	10	11	8	−30
Proceeds from sale of common stock equity, net of issuance costs	14	9	3	7	53
Proceeds from issuance of common stock upon exercise of warrants	3	—	—	—	2
Issuance costs of stock dividend	−10,277	—	—	—	—
Net cash provided by financing activities	17	9	−4	7	55
Net change in cash, cash equivalents	3	34,201	−12	−8	8
Recognition of operating lease right-of-use asset and liability	274,295	—	2	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro